Ascentage Pharma Group International

Equities

6855

KYG0519B1023

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:28 2024-05-24 EDT			5-day change	1st Jan Change
18.22 ^HKD	-4.21%		-11.34%	-33.26%

05-24	Ascentage Pharma to Present Four Studies on Anti-Cancer Drugs at US Oncology Meet; Shares Fall 4%	MT
05-24	Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting	CI

Guo Edward Ming to Retire as Chief Operating Officer of the Ascentage Pharma Group International, Effective October 31, 2021

August 30, 2021 at 10:40 am

The Board of Directors of Ascentage Pharma Group International announced Dr. Guo Edward Ming has decided to retire from the office of the Chief Operating Officer of the Company with effect from October 31, 2021.

Latest news about Ascentage Pharma Group International

Ascentage Pharma to Present Four Studies on Anti-Cancer Drugs at US Oncology Meet; Shares Fall 4%	05-23	MT
Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting	05-23	CI
Ascentage Pharma to Present Four Studies at US Oncology Meet	04-25	MT
Ascentage Pharma Chairman Boosts Stake in Firm	04-09	MT
Ascentage Pharma Group Directors Acquire Company Shares	04-03	MT
Ascentage Pharma Widens Loss by Nearly 5% in 2023	03-28	MT
Ascentage Pharma Group International Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Ascentage Pharma to Present Preclinical Results of Three Anti-Tumor Drugs at US Cancer Meet	03-05	MT
Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting	03-05	CI
Ascentage Pharma's Phase 3 Trial for Chronic Myeloid Leukemia Treatment Gets US FDA Nod; Shares Rise 3%	02-14	MT
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia	02-13	CI
Ascentage Pharma Trustee Buys 100,000 Shares	02-05	MT
Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia Management from the National Comprehensive Cancer Network	01-16	CI
Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib	12-14	CI
Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR	12-10	CI
Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication	11-24	CI
China Approves Ascentage Pharma's Chronic-Phase Chronic Myeloid Leukemia Treatment	11-19	MT
China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients	11-17	CI
Ascentage Pharma Group Trustee Purchases 100,000 Shares Under Restricted Share Scheme	11-16	MT
Ascentage Pharma Trustee Repurchases Shares	11-15	MT
Ascentage Pharma Trustee Buys 50,000 Shares Under Restricted Share Scheme	11-14	MT
Ascentage Pharma to Present Clinical Data on Hematological Drugs in US Meet	11-02	MT
Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM	11-02	CI
Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports	11-02	CI
Ascentage Pharma Presents Lung Cancer Therapy Study at European Oncology Conference	23-10-24	MT

Chart Ascentage Pharma Group International

Duration

Period

Chart Ascentage Pharma Group International

More charts

Company Profile

Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - American Society of Clinical Oncology Meeting - Abstract Number : 3124

More about the company

Income Statement Evolution

More financial data

Ratings for Ascentage Pharma Group International

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.89 CNY

Average target price

27.24 CNY

Spread / Average Target

+61.28%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ASCENTAGE PHARMA GROUP INTERNATIONAL	-33.26%	664M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs